ArticleCardio-oncology (London, England)2026
Nedaplatin induced QT prolongation with polymorphic ventricular tachyarrhythmia: clinical experience and review of literature.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNedaplatin (NDP), a cisplatin derivative, is widely employed in the treatment of solid tumours. Commonly reported adverse effects include hypersensitivity, myelosuppression and nephrotoxicity. To date, QT-interval prolongation and polymorphic ventricular tachyarrhythmia have not been attributed to NDP. A 41-year-old Asian woman was referred to our institution with abdominal pain, diarrhoea and vomiting. Percutaneous biopsy confirmed a diagnosis of high-grade serous carcinoma with widespread metastatic dissemination. She sequentially received a PD-1 inhibitor, paclitaxel and NDP. Twenty minutes after NDP infusion commenced she developed abdominal pain, palpitations, nausea and hypotension (68/39 mmHg). ECG disclosed marked QT prolongation, polymorphic ventricular tachycardia and Mobitz type I second-degree atrioventricular block. Advanced life-support measures were instituted immediately. Following withdrawal of the implicated agent and substitution with carboplatin, she remained asymptomatic during 48 h of monitoring.
conclusionWe report the case of marked QT-interval prolongation and polymorphic ventricular tachycardia temporally related to NDP administration. Clinicians should therefore monitor the electrocardiogram closely during NDP therapy, particularly in patients receiving polypharmacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.